Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)
Phase 2Active 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type II-Pompe's Disease
Conditions
Glycogen Storage Disease Type II-Pompe's Disease
Trial Timeline
Oct 12, 2017 → Aug 10, 2027
NCT ID
NCT03019406About Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) is a phase 2 stage product being developed by Sanofi for Glycogen Storage Disease Type II-Pompe's Disease. The current trial status is active. This product is registered under clinical trial identifier NCT03019406. Target conditions include Glycogen Storage Disease Type II-Pompe's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03019406 | Phase 2 | Active |
| NCT02782741 | Phase 3 | Completed |
Competing Products
20 competing products in Glycogen Storage Disease Type II-Pompe's Disease